BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback